(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.
Upstream Bio's earnings in 2026 is -$122,774,000.On average, 8 Wall Street analysts forecast UPB's earnings for 2026 to be -$171,653,584, with the lowest UPB earnings forecast at -$204,417,182, and the highest UPB earnings forecast at -$146,390,543. On average, 6 Wall Street analysts forecast UPB's earnings for 2027 to be -$197,905,532, with the lowest UPB earnings forecast at -$282,265,176, and the highest UPB earnings forecast at -$135,042,439.
In 2028, UPB is forecast to generate -$283,632,353 in earnings, with the lowest earnings forecast at -$462,851,340 and the highest earnings forecast at -$141,283,896.